

Value and kinetics of virological markers in the natural course of chronic hepatitis D virus infection

Lisa Sandmann^{1,2,3}, Valerie Ohlendorf¹, Alena Ehrenbauer¹, Birgit Bremer¹, Anke R.M. Kraft^{1,3,4,5}, Markus Cornberg^{1,2,3,4,5}, Katja Deterding¹, Heiner Wedemeyer^{1,2,3,4}, Benjamin Maasoumy^{1,4}

1) Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Germany, 2) D-SOLVE consortium, an EU Horizon Europe funded project, 3) Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany, 4) German Center for Infection Research (DZIF), Hannover/Braunschweig, Germany, 5) Centre for Individualised Infection Medicine (CiiM), a joint venture between Helmholtz-Centre for Infection Research and Hannover Medical School, Hannover, Germany

Background & Aim:

- Chronic hepatitis D virus (HDV) infection can cause severe liver disease.
- In the light of new treatment options, it is of particular importance to identify patients at risk for liver-related complications.
- We aimed to investigate the kinetics and predictive value of novel virological and immunological markers in the natural course of chronic HDV infection.

Methods:

- HBcrAg, HBV RNA and quantitative anti-HBc were analyzed in samples from patients with chronic HDV infection at three consecutive time points to study kinetics in the natural course of infection. Antiviral treatment conditions had to be similar at all study time points. Results were linked to clinical outcome.
- The primary endpoint was the composite endpoint of any liver-related event (hepatic decompensation, hepatocellular carcinoma, liver transplantation or liver-related death).
- Assays used in the study: HBV RNA: Roche Cobas 6800, LLOQ 10 cp/ml; HBcrAg: Lumipulse® G Fujirebio-Europe, LLOQ 3 log U/ml; Anti-HBc: Lumipulse® G Fujirebio-Europe, LLOQ 1 IU/ml; HDV RNA: RoboGene HDV RNA quantification kit 2.0 Roboscreen, LLOQ 82 IU/ml


Results:

Total, n	190
Male, n (%)	124 (65)
Age, years	41.3 (32.4-49.7)
HDV RNA (log IU/ml)	4.3 (2.55-5.54)
HDV RNA undetectable, n (%)	31 (16)
HBcrAg (log U/ml)	3.9 (2.9-4.73)
- HBcrAg ≥ 3 log U/ml, n (%)	141 (74)
 HBcrAg < 3 log U/ml or undetectable, n (%) 	49 (26)
HBV RNA (cop/ml) [#]	0 (0-10)
- HBV RNA ≥ 10 cop/ml, n (%)	20 (11)
- HBV RNA < 10 cop/ml or undetectable, n (%)	155 (89)
anti-HBc (IU/mI)	469 (123.5-1570)
HBV DNA (IU/ml)	20 (0-58.2)
HBsAg (IU/mI)	8490 (2250-14032)
HBeAg positive, n (%) [§]	25 (14)
ALT (U/L)	64 (38-132)
AST (U/L)	64 (40-94)
Platelets (x1000/µl)	135 (64-184.3)
Cirrhosis, n (%)	98 (52)
NA treatment, n (%)	82 (43)
Previous IFN treatment, n (%)	67 (35)
Total follow-up time (years)	2.69 (1.13-6.51)

Table 1. Baseline characteristics. Continuous parameters are depicted as median with IQR, categorical variables as number with percentage. #available for 175 patients, §available for 183 patients

Α

Baseline to 6 months (+/- 3 months)






Figure 2: Proportion of all (A) or HBeAg-negative (B) patients with concordant or discordant levels of HBcrAg or HBV RNA at study time points. Undetectable HBcrAg is defined as HBcrAg < 3 U/ml, undetectable HBV RNA is defined as HBV RNA < 10 IU/ml.

	Development of the combined endpoint			Multivariable analysis: Model A			Multivariable analysis: Model B		
	No (128)	Yes (62)	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Male, n (%)	79 (62)	45 (73)	0.140						
Age, years	38.1 (29.1-44.8)	50.1 (41.4-57.0)	<0.001	1.064	1.036-1.094	<0.001	1.063	1.034-1.092	<0.001
Cirrhosis, n (%)	42 (33)	56 (90)	<0.001	7.739	3.239-18.49	<0.001	7.355	3.112-17.38	<0.001
NA treatment	50 (39)	32 (52)	0.101						
IFN prior to BL	47 (37)	20 (32)	0.546						
HBV RNA (log cop/ml)#	0 (0-1)	0 (0-1)	0.764						
HBV RNA detectable #	17 (14)	3 (6)	0.093						
HBcrAg (log U/ml)	3.85 (2.63-4.7)	3.95 (3.08-4.8)	0.459						
HBcrAg detectable	93 (73)	48 (77)	0.482						
Anti-HBc (IU/mI)	587 (176-2246)	214 (51-667)	< 0.001	1.0	1.0-1.0	0.3341			
HBcrAg/anti-HBc ratio	1.40 (0.97-1.85)	1.69 (1.24-2.31)	0.002				1.096	0.8444-1.423	0.4899
HBsAg (IU/mI)§	8628 (2114-14071)	7016 (2250-12636)	0.593						
HDV RNA (log IU/ml)	4.19 (1.15-5.56)	4.78 (3.26-5.54)	0.184						
HDV RNA detectable	102 (80)	57 (92)	0.032	2.094	0.7928-5.532	0.1358	1.747	0.6845-4.461	0.2431

Table 2. Uni- and multivariate analysis of baseline characteristics of patients with and without the development of the combined

0		0	
U	BL	FU1	
n=73	Baseline	Follow-up 1	p-value
HDV RNA (log IU/ml)	4.36 (1.44-5.2)	3.86 (0-5.48)	0.1010
HBcrAg (log U/ml)	4.0 (2.85-4.60)	3.9 (2.0-4.65)	0.0142
HBV RNA (cop/ml)	0 (0-1)	0 (0-1)	0.3026
anti-HBc (IU/mI)	474 (69-1870)	332 (58-1505)	0.0018
HBsAg (IU/mI)	6549 (1788-14025)	5679 (1613-12630)	0.2119

Β **Baseline to 2-4 years (+/- 6 months)**




Figure 1: Comparison of median levels of virological parameters from baseline to FU1 (A) and baseline to FU2 (B). Median levels with interquartile range are depicted in the tables. Wilcoxon signed-rank test was used for comparison of medians.

endpoint (decompensation, HCC, LTx/death) during follow-up. Continuous parameters are depicted as median with IQR, categorical variables as number with percentage. Mann Whitney U test, Chi-Square or Fisher's exact test were used for group comparison. Multivariable Cox regression was used to address independent association of variables with the development of the combined endpoint during follow-up. # available for 120 and 55, respectively § available for 92 and 40, respectively

	Development of the combined endpoint Multivariable analysis				Table 3. Comparison of		
	No (n=42)	Yes (n=56)	p-value	Hazard ratio	95% CI	p-value	baseline characteristics
Male, n (%)	29 (69)	40 (71)	0.798				of patients with liver
Age, years	41.5 (33.2-47.6)	50.1 (41.4-55.3)	<0.001	1.046	1.008-1.087	0.019	cirrhosis with and
NA treatment	20 (48)	29 (52)	0.683				without the development
IFN prior to BL	14 (33)	18 (32)	0.901				of the combined endpoint
HBV RNA (log cop/ml)#	0 (0-0)	0 (0-0.25)	0.328				during follow-up.
HBV RNA detectable [#]	3 (7)	2 (4)	0.654				Continuous parameters are
HBcrAg (log U/ml)	3.8 (3.0-4.6)	3.85 (3.03-4.68)	0.752				depicted as median with
HBcrAg detectable	33 (79)	43 (77)	0.834				IQR, categorical variables
Anti-HBc (IU/ml)	433 (127-1335)	214 (51-644)	0.047	1.0	1.0-1.0	0.014	as number with
HBcrAg/anti-HBc ratio	1.45 (1.11-1.95)	1.67 (1.23-2.28)	0.102				percentage.
HBsAg (IU/mI) [§]	88818 (1419-11756)	7016 (2250-12608)	0.835				
HDV RNA (log IU/ml)	4.02 (1.53-5.46)	4.63 (3.01-5.46)	0.309				Mann Whitney U test, Chi-
HDV RNA detectable	34 (81)	51 (91)	0.144				Square or Fisher's exact
Sodium mmol/L	140 (137-141)	139 (137-141)	0.639				test were used for group
Creatinine µmol/L	69 (59-80)	66 (55-74)	0.117				comparison.
AST U/L	63 (38-89)	80 (56-105)	0.015	1.009	1.004-1.014	<0.001	Multivariable analysis was
ALT U/L	58 (36-117)	57 (38-105)	1.0				performed by cox
gGT U/L	74 (36-159)	71 (35-129)	0.909				regression analysis.
AP U/L	94 (69-128)	143 (106-172)	<0.001	1.005	1.001-1.010	0.011	Due to the strong baseline
CHE kU/L	5.19 (3.95-6.91)	3.47 (2.48-4.45)	<0.001	0.483	0.361-0.646	<0.001	correlation between INR
Bilirubin mmol/L	11 (9-19)	20 (16-46)	<0.001	1.006	1.0-1.012	0.043	and CHE (0.639), and CHE
Albumin g/L	40 (36-41)	33 (28-36)	< 0.001				and albumin (0.677) only
Platelets x1000/µl	84 (49.5-146.5)	58 (48-96)	0.023	1.0	1.0-1.0	0.021	CHE was included in the
INR	1.17 (1.09-1.26)	1.4 (1.23-1.63)	< 0.001				multivariable model.

available for 91 samples § available for 68 samples

Conclusion:

In this well-characterized cohort of 190 HDV-infected patients with a long follow-up, neither baseline levels nor kinetics of HBcrAg, HBV •

RNA or quantitative anti-HBc were independently associated with clinical outcome.

Stage of liver disease and age were predictors of liver-related events.

Quantitative anti-HBc was significantly lower in patients with liver cirrhosis and especially in those developing liver-related endpoints.

This encourages further research, particularly in the context of antiviral treatment that aims to achieve immunological control.

